•  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

 

One step ahead in biotechnology

mAbxience is a Chemo company specializing in the development and production of biologicals. It has two manufacturing facilities for active pharmaceutical ingredients: one in Buenos Aires, Argentina; and the other in León, Spain. Both plants have single-use bioreactors, a world-leading technology to ensure the purity and quality of medicines under the highest international quality standards. The development and production of monoclonal antibodies is supplemented with a partnership for the formulation and fractioning of these products with laboratory Sinergium Biotech.

Sinergium Biotech has the first plant in Argentina for the production of vaccines and biotechnologicals. The scientific and technological complex is located in Garín, Buenos Aires Province, and its integrated productive capacity reaches 30 million doses per year. The plant meets international Good Manufacturing Practices (GMP), in compliance with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) requirements.

Our products include biosimilar monoclonal antibodies used for the treatment of various cancer types, and autoimmune diseases such as rheumatoid arthritis, in addition to several recombinant proteins. Thus, biosimilars contribute to reduce the cost of biotechnologicals and expand access of patients to treatment for severe conditions.

These medicines are developed using the biosimilarity by design technology, which enables obtaining a biosimilar that is indistinguishable from the market reference product, also termed fingerprint-like similarity.

 

+ Read more

News Mabxience

(Español) 11/ 11/ 2020 Perfil

Hugo Sigman, sobre la vacuna de AstraZeneca: “Confiamos en que las pruebas serán exitosas”

El empresario es accionista de mAbxience, que se encargará de fabricar el principio activo de la inyección.  El calendario avanza y los laboratorios siguen a paso firme su producción de vacunas contra el coronavirus. La Administración Nacional de Medicamentos, Alimentos … Continue reading

+
(Español) 12/09/2020 Perfil

La relevancia de la cooperación público-privada

Para impulsar los proyectos de Investigación, Desarrollo e innovación (I+D+i) de envergadura, es necesaria la articulación público-privada. Estos proyectos son de alto riesgo tecnológico, y cuando tienen importancia estratégica para los países, como el caso de la vacuna anti- Covid-19, … Continue reading

+